A Randomized Phase II, Open-label, Multicenter Study Investigating Efficacy and Safety of Pembrolizumab +/- UV1 Vaccination as First Line Treatment in Patients With Inoperable Advanced or Metastatic Non-small Cell Lung Cancer
Latest Information Update: 13 Sep 2024
At a glance
- Drugs Atezolizumab (Primary) ; Cemiplimab (Primary) ; Pembrolizumab (Primary) ; Sargramostim (Primary) ; UV 1 (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms LUNGVAC
- 11 Sep 2024 According to an Ultimovacs media release, company announced that the company has agreed with the investigators conducting this trial to discontinue patient recruitment. The decision is driven by very slow recruitment in the study, which is primarily due to new treatment options available to NSCLC patients. All 31 patients that have been enrolled in the study since 2022 will be treated and followed up as per the trial protocol. Topline data from these patients expected in the first half of 2025.
- 11 Sep 2024 Status changed from recruiting to active, no longer recruiting, according to an Ultimovacs media release.
- 21 Aug 2024 According to an Ultimovacs ASA media release, as of date, 31 out of 138 patients have been enrolled in nine participating hospitals in Norway.